昊海生科收盘下跌2.34%，滚动市盈率30.14倍，总市值126.72亿元

Core Viewpoint - The company, Haohai Biological Technology Co., Ltd., is experiencing a decline in stock price and has a lower price-to-earnings (PE) ratio compared to the industry average, indicating potential undervaluation in the medical device sector [1][2]. Company Summary - Haohai Biological Technology's closing stock price is 54.34 yuan, down 2.34%, with a rolling PE ratio of 30.14 times and a total market capitalization of 12.672 billion yuan [1]. - The company operates in the medical device and pharmaceutical sectors, focusing on the research, production, and sales of products such as ophthalmic viscoelastic devices, artificial lenses, and hyaluronic acid [1]. - For the fiscal year 2024, the company reported revenue of 2.698 billion yuan, a year-on-year increase of 1.64%, and a net profit of 420 million yuan, reflecting a year-on-year growth of 1.04%, with a gross profit margin of 69.88% [1]. Industry Summary - The average PE ratio for the medical device industry is 45.94 times, with a median of 29.64 times, positioning Haohai Biological Technology at the 77th rank within the industry [2]. - The company has 7,605 shareholders as of February 29, 2020, an increase of 918 shareholders, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1].